Research Library › Incretin & Amylin
Retatrutide is an investigational single peptide, conjugated to a fatty diacid, that was designed to activate three hormone receptors: GIP, GLP-1 and glucagon. It was discovered at Eli Lilly under the code LY3437943 and described in a 2022 discovery paper. As of October 2026 it is not approved by the FDA or any other regulator; Lilly plans to file with the FDA in the first quarter of 2027, and the FDA has said federal law bars its use in compounding.
Key facts
| Type | Investigational synthetic peptide conjugated to a fatty diacid moiety |
|---|---|
| Other names | LY3437943 |
| Developed by | Eli Lilly and Company, Indianapolis, USA |
| First described | 2022, discovery-to-proof-of-concept paper in Cell Metabolism |
| Designed target | Triple agonist of the GIP, GLP-1 and glucagon receptors |
| Regulatory status (Oct 2026) | Not FDA-approved; Phase 3 (TRIUMPH program) ongoing; Lilly plans US submission in Q1 2027; FDA says it cannot lawfully be compounded |
Who developed it
Retatrutide was discovered and developed by Eli Lilly and Company. Lilly scientists described the molecule, then known as LY3437943, in a 2022 Cell Metabolism paper covering its path from discovery to early clinical proof of concept [1].
Lilly remains the developer and sponsors the Phase 3 trials, which it groups under the TRIUMPH name for obesity-related research and TRANSCEND for type 2 diabetes [2, 3].
Structure and design
Retatrutide is a single peptide conjugated to a fatty diacid moiety [4]. Lilly describes it as a first-in-class triple hormone receptor agonist, designed to act at the receptors for GIP, GLP-1 and glucagon within one molecule [2].
It extends a line of Lilly research on multi-receptor incretin molecules. Tirzepatide was designed to act at two of these receptors, GIP and GLP-1. Retatrutide adds activity at the glucagon receptor, a design that researchers proposed for study in metabolic disease programs [1, 2]. Any mechanism in people remains under clinical investigation.
Research history
- 2022: Lilly publishes the discovery of LY3437943 [1]
- June 2023: Phase 2 trial in obesity published in the New England Journal of Medicine [4]
- December 2025: Lilly reports the first completed Phase 3 trial, TRIUMPH-4 [5]
- July 2026: Lilly reports TRIUMPH-2 and TRIUMPH-3, completing the initial TRIUMPH registration program of four global trials with more than 5,800 participants [2]
- August 2026: Lilly states it plans a US submission in the first quarter of 2027 [6]
Lilly has said further Phase 3 trials are underway in other research areas, including chronic kidney disease and fatty liver disease [3].
Regulatory status as of October 2026
Retatrutide is not approved by the FDA or any other regulatory agency. Lilly states that it is available only to participants in Lilly-sponsored clinical trials [3]. In August 2026 the company said it planned to file with the FDA in the first quarter of 2027, for indications in obesity and related conditions [6].
The FDA states that federal law bars the use of retatrutide in compounding, because it is not a component of any FDA-approved drug. The agency has also warned telehealth companies, ingredient distributors and outsourcing facilities over retatrutide [7]. It has warned firms selling retatrutide labeled “for research purposes” or “not for human consumption” [7]. In a March 2026 warning letter, the FDA said a “Research Use Only” label did not change its finding that retatrutide sold online was an unapproved new drug [8]. Lilly has publicly warned that illicit products sold as retatrutide may contain unknown ingredients or impurities [3].
About this reference page
Kalibra Labs does not currently supply Retatrutide. This page is published as a neutral scientific and regulatory reference. Browse the Incretin & Amylin guide or the FDA Peptide Regulatory Tracker.
Frequently asked questions
Is retatrutide FDA approved?
No. As of October 2026 retatrutide is investigational and not approved anywhere; Lilly plans a US submission in the first quarter of 2027 [3, 6].
Who makes retatrutide?
Retatrutide was discovered and is being developed by Eli Lilly and Company under the code LY3437943 [1].
Why is retatrutide called a triple agonist?
It was designed as one molecule that activates three receptors: those for GIP, GLP-1 and glucagon [2].
How is retatrutide related to tirzepatide?
Both were developed by Eli Lilly. Tirzepatide was designed to act at the GIP and GLP-1 receptors, while retatrutide was designed to add the glucagon receptor as a third target [1, 2].
Can retatrutide be compounded?
No. The FDA states that federal law bars compounding with retatrutide because it is not part of any FDA-approved drug [7].
Sources
- Coskun T, Urva S, Roell WC, et al., Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi:10.1016/j.cmet.2022.07.013. Link
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (TRIUMPH-2, TRIUMPH-3). Press release, 23 Jul 2026. Link
- Eli Lilly and Company. What to know about retatrutide. Lilly news story, Sep/Oct 2026. Link
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972. Link
- Eli Lilly and Company. Press release on TRIUMPH-4 (NCT05931367), first Phase 3 trial of retatrutide. 11 Dec 2025. Link
- Eli Lilly and Company. Lilly reports second-quarter 2026 financial results. Press release, 5 Aug 2026. Link
- U.S. FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated 1 Oct 2026). Link
- U.S. FDA. Warning letter to Gram Peptides, MARCS-CMS 721806, 31 Mar 2026. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.
